Recognition of lipopolysaccharide pattern by TLR4 complexes

Experimental and Molecular Medicine

Volumn 45, Issue 12, 2013, Pages

  Park, Beom Seok ^a   Lee, Jie Oh ^b  

^a Eulji University   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

CD14; LBP; Lipopolysaccharide (LPS); MD 2; Toll like receptor 4 (TLR4)

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; CHOLESTEROL ESTER TRANSFER PROTEIN; LIPOPOLYSACCHARIDE BINDING PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHOLIPID TRANSFER PROTEIN; PROTEIN MD 2; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; LIPOPOLYSACCHARIDE;

BACTERIAL INFECTION; BACTERIAL OUTER MEMBRANE; GRAM NEGATIVE BACTERIUM; HUMAN; INFECTION RESISTANCE; INNATE IMMUNITY; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; CARBOHYDRATE ANALYSIS; CHEMISTRY; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CARBOHYDRATE SEQUENCE; HUMANS; IMMUNITY, INNATE; LIPOPOLYSACCHARIDES; MOLECULAR SEQUENCE DATA; TOLL-LIKE RECEPTOR 4;

EID: 84896575295     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2013.97     Document Type: Review

References (71)

1. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
2. Medzhitov R, Janeway C Jr. Innate immune recognition: mechanisms and pathways. Immunol Rev 2000; 173: 89-97.
3. Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem 2002; 71: 635-700.
4. Pugin J, Schurer-Maly CC, Leturcq D, Moriarty A, Ulevitch RJ, Tobias PS. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA 1993; 90: 2744-2748.
5. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999; 274: 10689-10692.
6. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420: 885-891.
7. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511.
8. Gay NJ, Gangloff M. Structure and function of Toll receptors and their ligands. Annu Rev Biochem 2007; 76: 141-165.
9. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
10. Maeshima N, Fernandez RC. Recognition of lipid A variants by the TLR4-MD-2 receptor complex. Front Cell Infect Microbiol 2013; 3: 3.
11. Trent MS, Stead CM, Tran AX, Hankins JV. Diversity of endotoxin and its impact on pathogenesis. J Endotoxin Res 2006; 12: 205-223.
12. Fujihara M, Muroi M, Tanamoto K, Suzuki T, Azuma H, Ikeda H. Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol Ther 2003; 100: 171-194.
13. Miyake K. Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2: unique roles for MD-2. Int Immunopharmacol 2003; 3: 119-128.
14. Mulero JJ, Boyle BJ, Bradley S, Bright JM, Nelken ST, Ho TT et al. Three new human members of the lipid transfer/lipopolysaccharide binding protein family (LT/LBP). Immunogenetics 2002; 54: 293-300.
15. Bingle CD, Craven CJ. Meet the relatives: a family of BPI-and LBP-related proteins. Trends Immunol 2004; 25: 53-55.
16. Beamer LJ, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science 1997; 276: 1861-1864.
17. Qiu X, Mistry A, Ammirati MJ, Chrunyk BA, Clark RW, Cong Y et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol 2007; 14: 106-113.
18. Huuskonen J, Wohlfahrt G, Jauhiainen M, Ehnholm C, Teleman O, Olkkonen VM. Structure and phospholipid transfer activity of human PLTP: analysis by molecular modeling and site-directed mutagenesis. J Lipid Res 1999; 40: 1123-1130.
19. Desrumaux C, Labeur C, Verhee A, Tavernier J, Vandekerckhove J, Rosseneu M et al. A hydrophobic cluster at the surface of the human plasma phospholipid transfer protein is critical for activity on high density lipoproteins. J Biol Chem 2001; 276: 5908-5915.
20. Kleiger G, Beamer LJ, Grothe R, Mallick P, Eisenberg D. The 1.7A crystal structure of BPI: a study of how two dissimilar amino acid sequences can adopt the same fold. J Mol Biol 2000; 299: 1019-1034.
21. Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995; 13: 437-457.
22. Haziot A, Ferrero E, Kontgen F, Hijiya N, Yamamoto S, Silver J et al. Resistance to endotoxin shock and reduced dissemination of gramnegative bacteria in CD14-deficient mice. Immunity 1996; 4: 407-414.
23. Kim JI, Lee CJ, Jin MS, Lee CH, Paik SG, Lee H et al. Crystal structure of CD14 and its implications for lipopolysaccharide signaling. J Biol Chem 2005; 280: 11347-11351.
24. Kelley SL, Lukk T, Nair SK, Tapping RI. The crystal structure of human soluble CD14 reveals a bent solenoid with a hydrophobic amino-terminal pocket. J Immunol 2013; 190: 1304-1311.
25. Kobe B, Kajava AV. The leucine-rich repeat as a protein recognition motif. Curr Opin Struct Biol 2001; 11: 725-732.
26. Dziarski R. Recognition of bacterial peptidoglycan by the innate immune system. Cell Mol Life Sci 2003; 60: 1793-1804.
27. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007; 130: 1071-1082.
28. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009; 458: 1191-1195.
29. Kang JY, Nan X, Jin MS, Youn SJ, Ryu YH, Mah S et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 2009; 31: 873-884.
30. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 2007; 130: 906-917.
31. Ohto U, Fukase K, Miyake K, Satow Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 2007; 316: 1632-1634.
32. Inohara N, Nunez G. ML - a conserved domain involved in innate immunity and lipid metabolism. Trends Biochem Sci 2002; 27: 219-221.
33. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007; 316: 1628-1632.
34. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008; 65: 3231-3240.
35. Rietschel ET, Kirikae T, Schade FU, Mamat U, Schmidt G, Loppnow H et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J 1994; 8: 217-225.
36. Ohto U, Yamakawa N, Akashi-Takamura S, Miyake K, Shimizu T. Structural analyses of human Toll-like receptor 4 polymorphisms D299G and T399I. J Biol Chem 2012; 287: 40611-40617.
37. Rossignol DP, Lynn M. TLR4 antagonists for endotoxemia and beyond. Curr Opin Investig Drugs 2005; 6: 496-502.
38. Piazza M, Calabrese V, Damore G, Cighetti R, Gioannini T, Weiss J et al. A synthetic lipid A mimetic modulates human TLR4 activity. ChemMed-Chem 2012; 7: 213-217.
39. Barochia A, Solomon S, Cui X, Natanson C, Eichacker PQ. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol 2011; 7: 479-494.
40. Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 2013; 497: 498-502.
41. Raetz CR, Reynolds CM, Trent MS, Bishop RE. Lipid A modification systems in gram-negative bacteria. Annu Rev Biochem 2007; 76: 295-329.
42. Ohto U, Fukase K, Miyake K, Shimizu T. Structural basis of speciesspecific endotoxin sensing by innate immune receptor TLR4/MD-2. Proc Natl Acad Sci USA 2012; 109: 7421-7426.
43. Kang JY, Lee JO. Structural biology of the Toll-like receptor family. Annu Rev Biochem 2011; 80: 917-941.
44. Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 2008; 320: 379-381.
45. Yoon SI, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL et al. Structural basis of TLR5-flagellin recognition and signaling. Science 2012; 335: 859-864.
46. Tanji H, Ohto U, Shibata T, Miyake K, Shimizu T. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. Science 2013; 339: 1426-1429.
47. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7: 353-364.
48. Kenny EF, O'Neill LA. Signalling adaptors used by Toll-like receptors: an update. Cytokine 2008; 43: 342-349.
49. Watters TM, Kenny EF, O'Neill LA. Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunol Cell Biol 2007; 85: 411-419.
50. Janssens S, Beyaert R. A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci 2002; 27: 474-482.
51. Song DH, Lee JO. Sensing of microbial molecular patterns by Toll-like receptors. Immunol Rev 2012; 250: 216-229.
52. Xu Y, Tao X, Shen B, Horng T, Medzhitov R, Manley JL et al. Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature 2000; 408: 111-115.
53. Nyman T, Stenmark P, Flodin S, Johansson I, Hammarstrom M, Nordlund P. The crystal structure of the human toll-like receptor 10 cytoplasmic domain reveals a putative signaling dimer. J Biol Chem 2008; 283: 11861-11865.
54. Khan JA, Brint EK, O'Neill LA, Tong L. Crystal structure of the Toll/ interleukin-1 receptor domain of human IL-1RAPL. J Biol Chem 2004; 279: 31664-31670.
55. Valkov E, Stamp A, Dimaio F, Baker D, Verstak B, Roversi P et al. Crystal structure of Toll-like receptor adaptor MAL/TIRAP reveals the molecular basis for signal transduction and disease protection. Proc Natl Acad Sci USA 2011; 108: 14879-14884.
56. Ohnishi H, Tochio H, Kato Z, Orii KE, Li A, Kimura T et al. Structural basis for the multiple interactions of the MyD88 TIR domain in TLR4 signaling. Proc Natl Acad Sci USA 2009; 106: 10260-10265.
57. Monie TP, Moncrieffe MC, Gay NJ. Structure and regulation of cytoplasmic adapter proteins involved in innate immune signaling. Immunol Rev 2009; 227: 161-175.
58. Gautam JK, Ashish Comeau LD, Krueger JK, Smith MF Jr. Structural and functional evidence for the role of the TLR2 DD loop in TLR1/TLR2 heterodimerization and signaling. J Biol Chem 2006; 281: 30132-30142.
59. Bovijn C, Ulrichts P, De Smet AS, Catteeuw D, Beyaert R, Tavernier J et al. Identification of interaction sites for dimerization and adapter recruitment in Toll/interleukin-1 receptor (TIR) domain of Toll-like receptor 4. J Biol Chem 2012; 287: 4088-4098.
60. Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 2010; 465: 885-890.
61. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001; 13: 933-940.
62. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002; 169: 10-14.
63. Hutchings MI, Palmer T, Harrington DJ, Sutcliffe IC. Lipoprotein biogenesis in Gram-positive bacteria: knowing when to hold 'em, knowing when to fold 'em. Trends Microbiol 2009; 17: 13-21.
64. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of doublestranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413: 732-738.
65. Choe J, Kelker MS, Wilson IA. Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science 2005; 309: 581-585.
66. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410: 1099-1103.
67. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303: 1526-1529.
68. Park B, Brinkmann MM, Spooner E, Lee CC, Kim YM, Ploegh HL. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat Immunol 2008; 9: 1407-1414.
69. Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi GP, Chapman HA et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008; 456: 658-662.
70. Kim YM, Brinkmann MM, Paquet ME, Ploegh HL. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature 2008; 452: 234-238.
71. Yoon SI, Hong M, Wilson IA. An unusual dimeric structure and assembly for TLR4 regulator RP105-MD-1. Nat Struct Mol Biol 2011; 18: 1028-1035.